
Clinical TrialsExplore Clinical Research at Nashville General
Advancing healthcare through innovative research and community collaboration.
Clinical Trials at NGH
Advancing medicine through compassionate research
Every medical breakthrough started with a simple question: "What if?" At NGH, our clinical trials program turns these questions into tomorrow's treatments, working hand-in-hand with a diverse patient population who share our vision for better healthcare.

For Patients Your Journey Matters
Clinical trials aren't just research studies – they're opportunities to access innovative treatments while helping future generations from all walks of life. Our dedicated team guides you through every step, from your first question to your final visit.
What to Expect:
- Personal support from our experienced research coordinators
- Clear, concise explanations of your rights and options
- Regular check-ups and careful monitoring
- Access to new treatment options- The satisfaction of advancing medical knowledge

For Investigators Transform Patient Care Through Research
Join our community of healthcare pioneers. NGH supports your research vision with state-of-the-art facilities and comprehensive research support services.
We Provide:
- Streamlined study startup processes
- Dedicated research coordinator support from one of our compassionate team members
- Access to diverse patient populations
- Full regulatory compliance assistance
- Industry-leading data management tools

For Sponsors and Industry Partners Innovation Through Collaboration
Partner with NGH to advance your clinical research goals. Our experienced team delivers high-quality data, efficient recruitment, and exceptional study management.
Why Choose NGH:
- Proven track record of successful trial completion
- Robust quality data management systems
- Experienced principal investigators across all disciplines
- Dedicated study coordination teams of nurses and support staff
- State-of-the-art imaging facilities and technology
Clinical Trials
NCT # Sort descending | Status | Title | Principle Investigator | Service Line |
---|---|---|---|---|
NCT06008093 | Enrolling | A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients (TRITON) The purpose of the study is to assess the efficacy of durvalumab plus tremelimumab in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy in metastatic NSCLC patients with non-squamous histology who have mutations and/or co-mutations in STK11, KEAP1, or KRAS. Sponsor: AstraZeneca |
Robin Jacob, MD | Dr. Robert E. Hardy Cancer Center |
NCT0601673 | Pending | A Phase 3 Randomized, Open-Label study of op-1250 Monotherapy vs standard of care for the treatment of ER+, HER2- Advanced or Metastatic, breast cancer following endocrine and CDK 4/6 Inhibitor Therapy ( OPERA-01) NCT06016738 Part 1 is closed. Part 2 opens March 2025.. This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine therapy in combination with a CDK4/6 inhibitor. Sponsor: Olema Pharmaceuticals, Inc. |
Robin Jacob, MD | Dr. Robert E. Hardy Cancer Center |
NCT06016738 | Active | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-01) This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine therapy in combination with a CDK4/6 inhibitor. Sponsor: Olema Pharmaceuticals, Inc. |
Robin Jacob, MD | Dr. Robert E. Hardy Cancer Center |
NCT06096779 | Enrolling | A Phase II, Open-Label, Multi-Cohort, Multicenter Study in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis The purpose of this study is to assess the safety and efficacy of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-Pugh B7 or B8 cirrhosis. Sponsor: Genentech, Inc. |
Robin Jacob, MD | Dr. Robert E. Hardy Cancer Center |
NCT06393374 | Enrolling | Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery. The primary objective is to compare sacituzumab tirumotecan plus pembrolizumab to TPC (pembrolizumab or pembrolizumab plus capecitabine) with respect to invasive disease-free survival (iDFS) per investigator assessment. It is hypothesized that sacituzumab tirumotecan plus pembrolizumab is superior to TPC with respect to iDFS per investigator assessment. Sponsor: Merck Sharp & Dohme LLC |
Robin Jacob, MD | Dr. Robert E. Hardy Cancer Center |
NCT06594523 | Pending | A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis (FASCINATE-3) A randomized, double-blind, placebo-controlled Phase 3 study to determine if denifanstat 50 mg or 25 mg is effective, as compared to placebo, in resolving MASH without the worsening of fibrosis and/or in fibrosis regression without the worsening of steatohepatitis. Sponsor: Sagimet Biosciences Inc. |
Robin Jacob, MD | Digestive Health (GI & Liver) |
NCT06692283 | Pending | A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH (FASCINIT) A phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and tolerability of denifanstat 50 mg compared to placebo in patients with metabolic dysfunction-associated steatotic liver disease (MALSD)/metabolic dysfunction-associated steatohepatitis (MASH) after 52 weeks of treatment. Sponsor: Sagimet Biosciences Inc. |
Robin Jacob, MD | Digestive Health (GI & Liver) |


Meet the Nashville General
Clinical Trials Team
Our Clinical Trials team at Nashville General Hospital is dedicated to advancing research and improving patient care. Led by experts in oncology, hepatology, population health, and clinical research, our team brings decades of experience in patient-centered studies, innovative treatments, and community engagement. Together, we ensure every trial is conducted with the highest standards of safety, integrity, and compassion.
Clinical Trials Articles
Contact the Clinical Trials Office
Lorem ipsum odor amet, consectetuer adipiscing elit. Vitae faucibus at enim egestas sapien eget erat. Lacus ullamcorper diam aptent nec nam placerat maximus dictumst class. Aporta diam scelerisque eleifend quam. Quam aptent aliquet commodo quam scelerisque nostra varius sem. Convallis est turpis justo justo sed feugiat
- Email:
- Phone Number: